drugset / Trial / NCT06785519
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
NaSingle-groupOpen-labelTreatment
Summary
A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.
Timeline
- Start
- 2025-01-31
- Primary completion
- 2027-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/BCMA Lupus Nephritis Targeted CAR T-cells | Cell therapy | — | Intravenous |